The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency

Arora P, Rocha C, Kempf A, Nehlmeier I, Graichen L, Winkler MS, Lier M, Schulz S, Jäck HM, Cossmann A, Stankov MV, Behrens GMN, Pohlmann S, Hoffmann M (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Cellular & Molecular Immunology Nature Publishing Group: Open Access Hybrid Model Option A

DOI: 10.1038/s41423-021-00779-5

Authors with CRIS profile

Sebastian Schulz Professur für Immunologie Hans-Martin Jäck Department of Molecular Immunology

Involved external institutions

Deutsches Primatenzentrum (DPZ), Leibniz-Institut für Primatenforschung DE Germany (DE) Georg-August-Universität Göttingen DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE)

How to cite

APA:

Arora, P., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Winkler, M.S.,... Hoffmann, M. (2021). The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. Cellular & Molecular Immunology. https://doi.org/10.1038/s41423-021-00779-5

MLA:

Arora, Prerna, et al. "The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency." Cellular & Molecular Immunology (2021).

BibTeX: Download